{"id":"y-3-for-injection","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Rash"},{"rate":"1-5%","effect":"Pneumonitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to PD-1, Y-3 for injection blocks the interaction between PD-1 and its ligands, leading to the activation of T cells and an anti-tumor immune response. This results in the killing of cancer cells and the slowing of tumor growth.","oneSentence":"Y-3 for injection is a monoclonal antibody that targets the PD-1 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:14.229Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"},{"name":"Head and neck squamous cell carcinoma"}]},"trialDetails":[{"nctId":"NCT06770491","phase":"PHASE1","title":"A Phase 1 Study of Y-3 in US Healthy Volunteers.","status":"COMPLETED","sponsor":"Neurodawn Pharmaceutical Co., Ltd.","startDate":"2025-02-04","conditions":"Safety, Tolerability, Pharmacokinetic Study in Healthy Volunteers","enrollment":20},{"nctId":"NCT07068841","phase":"PHASE1","title":"Pharmacokinetic Effect of Y-3 on Repaglinide，Warfarin and Omeprazole in Healthy Participants","status":"COMPLETED","sponsor":"Neurodawn Pharmaceutical Co., Ltd.","startDate":"2025-05-18","conditions":"Pharmacokinetic Profiles, Y-3 for Injection, Drug-drug Interaction","enrollment":24},{"nctId":"NCT04229979","phase":"PHASE3","title":"Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sellas Life Sciences Group","startDate":"2021-02-08","conditions":"Acute Myeloid Leukemia","enrollment":127},{"nctId":"NCT07055412","phase":"PHASE1","title":"Y-3 for Injection in Patients With Hepatic Insufficiency and Healthy Subjects","status":"NOT_YET_RECRUITING","sponsor":"Neurodawn Pharmaceutical Co., Ltd.","startDate":"2025-07-10","conditions":"Pharmacokinetic Differences, Y-3, Saftey","enrollment":24},{"nctId":"NCT06374667","phase":"NA","title":"The Efficacy and Safety of Y-3 Intracalvariosseous Injection Versus Intravenous Injection in the Treatment of Acute Large Hemispheric Infarction","status":"RECRUITING","sponsor":"yilong Wang","startDate":"2024-04-22","conditions":"Stroke, Acute Ischemic, Blood-Brain Barrier","enrollment":134},{"nctId":"NCT06517173","phase":"PHASE3","title":"Y-3 for Injection in the Treatment of Acute Ischemic Stroke","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2024-07-24","conditions":"Acute Ischemic Stroke","enrollment":998},{"nctId":"NCT06429384","phase":"PHASE2","title":"Y-3 Injection in the Treatment of Acute Ischemic Stroke Phase II Clinical Trial","status":"COMPLETED","sponsor":"Beijing Tiantan Hospital","startDate":"2023-06-04","conditions":"Acute Ischemic Stroke","enrollment":240},{"nctId":"NCT05849805","phase":"NA","title":"Y-3 Injection Through Skull Bone Marrow in the Treatment of Acute Malignant Middle Cerebral Artery Infarction (SOLUTION)","status":"COMPLETED","sponsor":"Beijing Tiantan Hospital","startDate":"2023-04-17","conditions":"Stroke, Acute Ischemic","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Y-3 for injection","genericName":"Y-3 for injection","companyName":"Beijing Tiantan Hospital","companyId":"beijing-tiantan-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Y-3 for injection is a monoclonal antibody that targets the PD-1 receptor. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}